A substudy of the Evolut Low Risk Trial assessed the incidence and clinical impact of valve leaflet thickening and restricted mobility after transcatheter aortic valve replacement (TAVR) and surgical AVR… Click to show full abstract
A substudy of the Evolut Low Risk Trial assessed the incidence and clinical impact of valve leaflet thickening and restricted mobility after transcatheter aortic valve replacement (TAVR) and surgical AVR (SAVR). ECG-gated multi-detector computed tomography (CT) scans at baseline, 30 days, and 1
Keywords:
low risk;
evolut low;
substudy;
leaflet thickening
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!